-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medicine Network November 24 - Acute myeloid leukemia (AML) is a tumor that affects blood and bone marrow, and its incidence increases with age.
AML is one of the most common types of leukemia in adults.
Reporters learned on the 24th, for the treatment of adult patients with FLT3 mutation relapsed or refractory acute myeloid leukemia fumaric acid ginni tablets (collectively referred to as gilitinib) was included in the Third Batch of China's State Drug Administration Drug Review Center (CDE) clinically in urgent need of foreign new drugs list.
understand that the innovative drug's new drug licensing application has been included in the priority review.
about 80,000 people in China are diagnosed with leukemia each year.
In the past ten years, the treatment of recurring incurable acute myeloid leukemia has been slow, with short survival and many complications, except for resurrive chemotherapy and hematopoietic stem cell transplantation.
it is understood that the emergence of gininib will break through the status quo of drug-free.
, it is understood that prior to the United States, Japan, the European Union, some countries and regions to bring the gospel to patients.
。
